KR101672401B1 - 암 줄기 세포를 가시화하고 제거하기 위한 조성물 및 방법 - Google Patents

암 줄기 세포를 가시화하고 제거하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR101672401B1
KR101672401B1 KR1020117022422A KR20117022422A KR101672401B1 KR 101672401 B1 KR101672401 B1 KR 101672401B1 KR 1020117022422 A KR1020117022422 A KR 1020117022422A KR 20117022422 A KR20117022422 A KR 20117022422A KR 101672401 B1 KR101672401 B1 KR 101672401B1
Authority
KR
South Korea
Prior art keywords
prolactin receptor
patient
receptor antagonist
cancer
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117022422A
Other languages
English (en)
Korean (ko)
Other versions
KR20110139703A (ko
Inventor
원 와이. 첸
Original Assignee
온코릭스, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코릭스, 아이엔씨. filed Critical 온코릭스, 아이엔씨.
Publication of KR20110139703A publication Critical patent/KR20110139703A/ko
Application granted granted Critical
Publication of KR101672401B1 publication Critical patent/KR101672401B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5756—Prolactin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020117022422A 2009-02-26 2010-02-16 암 줄기 세포를 가시화하고 제거하기 위한 조성물 및 방법 Expired - Fee Related KR101672401B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15562409P 2009-02-26 2009-02-26
US61/155,624 2009-02-26
PCT/US2010/024340 WO2010099003A2 (en) 2009-02-26 2010-02-16 Compositions and methods for visualizing and eliminating cancer stem cells

Publications (2)

Publication Number Publication Date
KR20110139703A KR20110139703A (ko) 2011-12-29
KR101672401B1 true KR101672401B1 (ko) 2016-11-16

Family

ID=42133705

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117022422A Expired - Fee Related KR101672401B1 (ko) 2009-02-26 2010-02-16 암 줄기 세포를 가시화하고 제거하기 위한 조성물 및 방법

Country Status (9)

Country Link
US (1) US8754035B2 (https=)
EP (1) EP2400979B1 (https=)
JP (2) JP5963443B2 (https=)
KR (1) KR101672401B1 (https=)
CN (2) CN106177954A (https=)
AU (1) AU2010218261B2 (https=)
CA (1) CA2753804C (https=)
IL (2) IL214545A (https=)
WO (1) WO2010099003A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8648046B2 (en) * 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
EP2576823A1 (en) * 2010-06-04 2013-04-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Constitutively active prolactin receptor variants as prognostic markers and therapeutic targets to prevent progression of hormone-dependent cancers towards hormone-independence
CN105102480B (zh) 2012-12-24 2019-04-16 艾伯维公司 催乳素受体结合蛋白及其用途
EP3157547A1 (en) * 2014-06-18 2017-04-26 Prorec Bio AB Prolactin receptor antagonists for treatment of glioblastoma
CN107198779A (zh) * 2016-11-29 2017-09-26 南京东纳生物科技有限公司 一种干细胞标记示踪及靶向导航的纳米偶联复合物及其制备方法和应用
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
WO2020011998A1 (en) * 2018-07-13 2020-01-16 Hifibio Sas Use of droplet single cell epigenome profiling for patient stratification
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515404A (ja) 1998-05-12 2002-05-28 ウェン ワイ． シェン 増殖性疾患を治療するための抗プロラクチン剤の使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1055932A (en) 1975-10-22 1979-06-05 Hematech Inc. Blood substitute based on hemoglobin
DE2616086C2 (de) 1976-04-13 1986-04-03 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Substanz zur Verwendung in einem kolloidalen Blutvolumenersatzmittel aus Hydroxyethylstärke und Hämoglobin
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1282642B1 (en) 2000-05-09 2006-09-06 Greenville Hospital System Therapeutic pore-forming peptides
EP1411922A1 (en) * 2001-07-31 2004-04-28 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
US7001888B2 (en) * 2002-03-29 2006-02-21 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
BR0314106A (pt) 2002-09-11 2005-07-19 Fresenius Kabi De Gmbh Polipeptìdeos hasilados, especialmente eritropoietina hasilada
NZ541122A (en) * 2002-12-26 2008-09-26 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
US8754031B2 (en) 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
US20050238628A1 (en) * 2004-04-08 2005-10-27 Blau Carl A Methods for treating cancer
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
WO2009089537A2 (en) * 2008-01-11 2009-07-16 Northwestern University Anti-cancer compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515404A (ja) 1998-05-12 2002-05-28 ウェン ワイ． シェン 増殖性疾患を治療するための抗プロラクチン剤の使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Breast Cancer Research 2008, 10:R68
Breast Cancer Research and Treatment, September 2008, Volume 111, Issue 2, pp 241-250.

Also Published As

Publication number Publication date
IL214545A0 (en) 2011-09-27
EP2400979A2 (en) 2012-01-04
CN102341118A (zh) 2012-02-01
JP5963443B2 (ja) 2016-08-03
US8754035B2 (en) 2014-06-17
CN106177954A (zh) 2016-12-07
EP2400979B1 (en) 2015-05-20
AU2010218261B2 (en) 2015-08-20
JP2012519168A (ja) 2012-08-23
KR20110139703A (ko) 2011-12-29
US20100215577A1 (en) 2010-08-26
JP2014156484A (ja) 2014-08-28
CA2753804A1 (en) 2010-09-02
WO2010099003A3 (en) 2011-02-17
IL246247A0 (en) 2016-07-31
WO2010099003A2 (en) 2010-09-02
IL214545A (en) 2016-07-31
AU2010218261A1 (en) 2011-09-01
CA2753804C (en) 2018-03-13

Similar Documents

Publication Publication Date Title
KR101672401B1 (ko) 암 줄기 세포를 가시화하고 제거하기 위한 조성물 및 방법
EP2640412B1 (en) Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer
AU2003237347A1 (en) Treatment of cell proliferative disorders with chlorotoxin
CN104271590A (zh) 用于癌治疗的肽剂
JP2009527498A (ja) 癌におけるｃａＰＣＮＡ相互作用のペプチドによる抑制
JP2011504361A (ja) 肝細胞癌細胞に特異的なペプチドおよびその適用
CN102134275B (zh) 表皮生长因子受体变异体
TW201200151A (en) Methods and compositions related to reduced MET phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells
CN118005730A (zh) 靶向p53突变蛋白的抗肿瘤多肽及其应用、抗癌药物组合物
HK1231758A1 (en) Compositions and methods for visualizing and eliminating cancer stem cells
HK1231759A1 (en) Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer
US20260061085A1 (en) Cyclic peptide and preparation method therefor, and complex comprising same and use thereof
HK1166693A (en) Compositions and methods for visualizing and eliminating cancer stem cells
HK1189171A (en) Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer
US20140005119A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS
EP3984547A1 (en) Peptides for the treatment of cancer
US10201610B2 (en) Interference peptides and use thereof
LT4877B (lt) Prv-1 genas ir jo panaudojimas
WO2014129969A1 (en) Therapeutic agents

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20191029

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20191029

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000